News

Co-occurrence of Cancer Driver Genes is Key to Precision Medicine

System predicts tumor response to different treatments

Brought to you byInstitute for Research in Biomedicine
| 2 min read
cancer cell division
Register for free to listen to this article
Listen with Speechify
0:00
2:00

Cancer driver genes are those with mutations that are essential for tumor development and spread. Led by ICREA researcher Patrick Aloy, scientists from the Structural Bioinformatics and Network Biology (SBNB) Laboratory at IRB Barcelona have developed a computational pipeline that predicts tumor response to different cancer treatments. This system is based on the identification of complex response markers derived from the patterns of co-occurrence between cancer driver genes carrying mutations. It has been tested experimentally and with data from breast cancer patients and has achieved 66 percent accuracy in the prediction of these responses.

To continue reading this article, sign up for FREE
Today's Clinical Lab Logo
Membership is FREE and provides you with instant access to eNewsletters, digital publications, article archives, and more.
Unlock for FREE
Add Today's Clinical Lab as a preferred source on Google

Add Today's Clinical Lab as a preferred Google source to see more of our trusted coverage.

Related Topics